ImmuCell Corporation (ICCC)vsRegeneron Pharmaceuticals Inc (REGN)
ICCC
ImmuCell Corporation
$9.95
-4.05%
HEALTHCARE · Cap: $94.18M
REGN
Regeneron Pharmaceuticals Inc
$902.99
-2.98%
HEALTHCARE · Cap: $95.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 54980% more annual revenue ($16.90B vs $30.68M). REGN leads profitability with a 28.5% profit margin vs 2.6%. REGN trades at a lower P/E of 20.5x. REGN earns a higher WallStSmart Score of 78/100 (B+).
ICCC
Hold45
out of 100
Grade: D
REGN
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+63.2%
Fair Value
$17.65
Current Price
$9.95
$7.70 discount
Margin of Safety
+38.3%
Fair Value
$1504.34
Current Price
$902.99
$601.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 259.9% YoY
Reasonable price relative to book value
Strong operational efficiency at 26.9%
Strong operational efficiency at 40.5%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
2.6% margin — thin
Premium valuation, high expectations priced in
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ICCC
The strongest argument for ICCC centers on EPS Growth, Price/Book, Operating Margin. Revenue growth of 11.5% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 40.5%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : ICCC
The primary concerns for ICCC are Altman Z-Score, Market Cap, Profit Margin. A P/E of 148.1x leaves little room for execution misses. Thin 2.6% margins leave little buffer for downturns.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ICCC profiles as a value stock while REGN is a growth play — different risk/reward profiles.
ICCC carries more volatility with a beta of 0.62 — expect wider price swings.
REGN is growing revenue faster at 36.3% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (78/100 vs 45/100), backed by strong 28.5% margins and 36.3% revenue growth. ICCC offers better value entry with a 63.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmuCell Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
ImmuCell Corporation, an animal health company, develops, manufactures and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. The company is headquartered in Portland, Maine.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?